6737-62-8

Basic information

• Product Name: AKOS BBS-00005389
• Synonyms: AKOS BBS-00005389;ASISCHEM U53257;6-Chloro-N,N'-bis(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine
• CAS NO: 6737-62-8
• Molecular Formula: C₁₇H₁₆ClN₅O₂
• Molecular Weight: 357.79
• Mol File: 6737-62-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BBS-00005389(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BBS-00005389(6737-62-8)
• EPA Substance Registry System: AKOS BBS-00005389(6737-62-8)

Safety Data

• Hazardous Substances Data: 6737-62-8(Hazardous Substances Data)

Upstream product

• 30377-27-6 4,6-dichloro-N-(4-methoxyphenyl)-1,3,5-triazin-2-amine 
• 104-94-9 4-methoxy-aniline 
• 754207-98-2 2,4-dichloro-6-[N-(4'-ethoxyphenyl)dithiocarbamoyl]-s-triazine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 

Downstream Products

• 1084910-23-5 C₂₅H₂₄N₆O₂S₂ 
• 1450982-29-2 6-(4-(2-((7-chloroquinolin-4-yl)amino)ethyl)piperazin-1-yl)-N²,N⁴-bis(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine 
• 1584056-02-9 2-N-{2-[bis(2-{10β-dihydroartemisinoxy}ethyl)amino]ethyl}-4-N,6-N-bis(4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 1584055-70-8 2-N-(2-aminoethyl)-4-N,6-N-bis(4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 1607446-30-9 N,N'-bis[4,6-bis(4-methoxyphenylamino)-1,3,5-triazin-2-yl]-p-phenylenediamine 
• 351985-61-0 N²,N⁴-bis(4-methoxyphenyl)-6-(piperazin-1-yl)-1,3,5-triazine-2,4-diamine 
• 1453805-41-8 4-(4,6-bis(4-methoxyphenylamino)-1,3,5-triazin-2-yl)-N-(7-chloroquinolin-4-yl)piperazine-1-carbothioamide 
• 1422249-35-1 C₃₃H₃₂N₈O₃ 
• 1422249-34-0 C₃₂H₂₉N₉O₄ 
• 1422249-33-9 C₃₂H₂₉ClN₈O₂ 
• 1422249-32-8 C₃₂H₂₉ClN₈O₂ 
• 1422249-31-7 C₃₄H₃₅N₉O₂ 
• 1422249-30-6 C₃₂H₃₀N₈O₃ 
• 1422249-29-3 C₃₂H₂₉N₉O₄ 

Relevant articles and documents

Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4-aminoquinoline-1,3,5-triazine derivatives

A series of 4-aminoquinoline 1,3,5-triazine derivatives were synthesized and evaluated for anticancer activity against cancer cell lines HeLa, MCF-7, HL-60, HepG2 where these derivatives exert significant anticancer activity. The molecules found nontoxic against MCF-12A. The molecules also showed potent inhibition of EGFR-TK as compared to eroltinib in enzyme-based assay. The newly synthesized derivatives were screened for their in vitro antibacterial and antifungal activity against Bacillus subtilis, Bacillus cereus, Staphylococcus aureus, Proteus vulgaris, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, Aspergillus niger, Aspergillus fumigatus using cefixime and fluconazole as standard. Antibacterial screening results suggest that compound 7c showed potent activity against S. aureus, P. aeruginosa, and P. vulgaris. In antifungal screening, compound 7b showed significant activity against A. niger, A. fumigatus and moderate activity against C. albicans.

Cardioprotective effect of novel sulphonamides-1,3,5-triazine conjugates against ischaemic–reperfusion injury via selective inhibition of MMP-9

Diseases affecting cardiovascular system are ranked as a top most cause of morbidity and mortality. Herein, a novel class sulphonamides-1,3,5-triazine conjugates have been synthesized and tested for inhibitory activity against MMP-2 and MMP-9. The results of the study showed that these molecules efficiently inhibit MMP-9 than MMP-2, revealing compound 8e as the most potent inhibitor (IC50?=?2.34?±?0.56?nm). Due to involvement of MMP-9 in many cardiovascular diseases, particularly in myocardial ischaemia (MI), compound 8e was further subjected for the determination of the protective effect on isoproterenol (ISO)-induced myocardial injury in rats.

Antimalarial activity and docking studies of novel bi-functional hybrids derived from 4-aminoquinoline and 1,3,5-triazine against wild and mutant malaria parasites as pf-DHFR inhibitor

Bi-functional conjugates comprised of 4-aminoquinoline and 1,3,5-triazine were synthesized through facile synthetic routes. These compounds were rigorously screened for determination of their antimalarial activity against wild and mutant cultured Plasmodium falciparum. The results disclosed that the conjugates have considerable antimalarial activity against both wild and mutant parasites with marked variation on changing the pattern of substitutions. The observed activity profiles were additionally substantiated by docking studies on both wild and quadruple mutant P. falciparum dihydrofolate reductase thymidylate synthase (pf-DHFR-TS).